JAC Advance Access published online on December 12, 2002
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg046
© 2002 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Paper
1 Research and Development, Ribapharm, Inc., 3300 Hyland Avenue,
Costa Mesa, CA 92626, USA
* Corresponding author. E-mail: cclin{at}ribapharm.com.
Received 7 February 2002
; revised 2 July 2002
; accepted 20 August 2002
The absorption, pharmacokinetics and excretion of levovirin
were studied in Sprague-Dawley rats (30 mg/kg) and Beagle
dogs (30 mg/kg) following intravenous (iv) and oral administration
of [3H]levovirin, and in Cynomolgus
monkeys following iv and oral administration of [14C]levovirin. Oral
absorption was 31.3% in rats, 67.3% in dogs and
17.5% in monkeys, and the bioavailability was 29.3% in
rats, 51.3% in dogs and 18.4% in monkeys. After
iv administration, the elimination half-life (t1/2)
was 1.47 h in rats, 3.70 h in dogs and 3.50 h in monkeys. The total
body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively,
in rats, dogs and monkeys and the apparent volume of distribution
was 0.79, 0.95 and 0.65 L/kg. No metabolite was detected in plasma
or urine of rats, dogs or monkeys, indicating negligible metabolism
of levovirin in these animals. Excretion of total radioactivity
in urine after oral dosing accounted for 15.4% of the administered dose
in rats, 49.9% in dogs and 21.4% in monkeys. Biliary
excretion did not play a significant role in the elimination of
levovirin.
Keywords: levovirin, hepatitis C, metabolism, pharmacokinetics
Absorption, pharmacokinetics and excretion of levovirin
in rats, dogs and Cynomolgus monkeys
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Michaelis, R. Michaelis, T. Suhan, H. Schmidt, A. Mohamed, H. W. Doerr, and J. Cinatl Jr. Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion FASEB J, January 1, 2007; 21(1): 81 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Huang, S. Ostrowitzki, G. Hill, M. Navarro, N. Berger, P. Kopeck, C. I. Mau, T. Alfredson, and R. Lal Single- and Multiple-Dose Pharmacokinetics of Levovirin Valinate Hydrochloride (R1518) in Healthy Volunteers J. Clin. Pharmacol., May 1, 2005; 45(5): 578 - 588. [Abstract] [Full Text] [PDF] |
||||

